The chapter delves into a study on a new drug for sleep apnea, emphasizing the need for further research and affordability for widespread use. It also covers the considerations and challenges associated with transitioning from a CPAP machine to a drug intervention. Additionally, it discusses various business deals in the industry, such as UPS selling its Coyote Logistics Unit and the partnership between Target and Shopify to enhance Target's marketplace offering.
ResMed has had the market on sleep apnea cornered for a while, but new weight-loss drugs might be creeping in. We look at what could change based on recent studies and some other businesses that have established lifelong customers.
(00:21) Bill Barker and Dylan Lewis discuss:
- How weight-loss drugs like Eli Lilly’s Zepbound might be coming for ResMed and the sleep apnea market.
- RXO take a bigger piece of the brokered transportation market, scooping up Coyote Logistics from UPS.
- Target and Shopify linking up for a win-win partnership.
(13:02) Tim Beyers and Ricky Mulvey discuss the value of lifetime-customer relationships, why they’re huge for the likes of Apple, and Costco, and one lesser-known name that may have one too.
Companies discussed: LLY, NVO, RMD, SPOT, AAPL, SNOW
Host: Dylan Lewis
Guests: Tim Beyers, Tim Beyers, Ricky Mulvey
Producer: Ricky Mulvey
Engineers: Dan Boyd
Learn more about your ad choices. Visit megaphone.fm/adchoices